(Q67720631)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

title

Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

10 November 2022

author name string

J. H. Schiller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

P. L. Witt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

B. Storer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

D. Alberti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

M. B. Tombes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

R. Arzoomanian

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

R. R. Brown

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

R. A. Proctor

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

S. D. Voss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

D. R. Spriggs

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728387

10 November 2022

language of work or name

English

0 references

publication date

1 January 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

15 January 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1728387

full work available at URL

10 November 2022

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

10 November 2022

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

10 November 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

page(s)

562-571

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon

17 September 2019

cites work

1

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

10 November 2022

2

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay

10 November 2022

5

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents

10 November 2022

7

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Successful treatment of colon cancer in rats with recombinant interferon-gamma

10 November 2022

8

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide

10 November 2022

10

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma

10 November 2022

11

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Proceedings of the American Association for Cancer Research

10 November 2022

13

28

338

Datta

1987

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha

10 November 2022

14

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

10 November 2022

20

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Phase I trial of recombinant interferon gamma in cancer patients

10 November 2022

21

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Phase I study of multiple dose intramuscularly administered recombinant gamma interferon

10 November 2022

22

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans

10 November 2022

28

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

10 November 2022

30

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity

10 November 2022

31

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages

10 November 2022

33

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Direct and steam distillation autoanalyzer methods for assay of diazotizable aromatic amine metabolites of tryptophan in urine and in serum

10 November 2022

35

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha

10 November 2022

36

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

10 November 2022

38

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

The soluble interleukin-2 receptor: biology, function, and clinical application

10 November 2022

39

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients

10 November 2022

40

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo

10 November 2022

41

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

10 November 2022

44

1 reference

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C562::AID-CNCR2820690247%3E3.0.CO;2-0

10 November 2022

Identifiers

10.1002/1097-0142(19920115)69:2<562::AID-CNCR2820690247>3.0.CO;2-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1728387%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference